Biogen Leans On Pipeline As Tecfidera, Spinraza See Q4 Sales Dip

Aducanumab Added To 2021 Guidance Amid Approval Optimism

 
• By Alaric DeArment

The company sees aducanumab adding a modest boost to sales if approved, but there are another four Phase III programs with some major read-outs coming.

Alzheimers_677117191_Atthapon-Raksthaput_1200.jpg
Biogen leans on aducanumab and other pipeline drugs as sales of Tecfidera and Spinraza slumped in Q4 and 2020. • Source: Shutterstock

More from Business

More from Scrip